QuantAbundanciaAbundance, Quantified.

News

High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.

20,995 signal articles · 490 in last 24h · 103,318 total before filter · latest 1h ago
490last 24h
2474last 7d
479● bullish (7d)
251● bearish (7d)
197publishers
AllMacro243Earnings1482M&A141Regulatory16Product4Analyst29
✕ clear all filtersticker: CVSSentiment:bullishneutralbearish✓ showing all (incl. clickbait)
CVS Health (CVS) Faces Henry Ford Health Lawsuit Over $29 Million 340B Claims
Simply Wall St.12d agobearish
CVS Health (CVS) Faces Henry Ford Health Lawsuit Over $29 Million 340B Claims

Henry Ford Health has filed a lawsuit against CVS Health (NYSE:CVS) alleging fraudulent reimbursement practices tied to the federal 340B drug discount program. The complaint claims CVS manipulated pricing and engaged in retaliatory behavior, which Henry Ford Health says led to losses of more than US$29 million. The case adds to a series of disputes between large health systems and pharmacy operators over how 340B program discounts are administered. For investors following CVS Health, this...

FTC Reaches Settlement With CVS Health Over Insulin Prices
Barrons.com21d agoneutral
FTC Reaches Settlement With CVS Health Over Insulin Prices

The Federal Trade Commission announced a settlement with CVS Health’s pharmacy benefit manager business on Tuesday, the agency’s second major agreement this year with drug industry middlemen. Pharmacy-benefit managers, or PBMs, play a key role in negotiating with drug companies and selecting which prescription drugs will be covered by an insurance plan. In litigation filed in 2024 during the Biden administration, the commission alleged that rebates and fees collected by major PBMs from drug manufacturers artificially inflated the price of insulin.

CVS Health (CVS) Under the Microscope After Recent Healthcare Report
Insider Monkey43d agoneutral
CVS Health (CVS) Under the Microscope After Recent Healthcare Report

CVS Health Corporation (NYSE:CVS) is one of the 10 Cheap Jim Cramer Stocks to Invest In Right Now. The New York Times, in an article published on June 11, 2026, pointed to two federal reports from the Department of Health and Human Services and stated that CVS Health Corporation (NYSE:CVS) and other major Medicare Advantage […]

CVS Health Balances 340B Lawsuits With GLP 1 Growth Prospects
Simply Wall St.60d agobearish
CVS Health Balances 340B Lawsuits With GLP 1 Growth Prospects

CVS Health (NYSE:CVS) is facing lawsuits from multiple health systems that allege the company diverted hundreds of millions of dollars in savings tied to the federal 340B drug discount program. At the same time, CVS Health is expanding access to GLP-1 weight management drugs through new formulary decisions, including the reintroduction of Zepbound and removal of barriers for Foundayo. These developments come as pharmacy benefit manager practices receive increased attention from regulators...

CVS Health Lawsuits Test 340B Practices And Investor Risk Assessment
Simply Wall St.76d agobearish
CVS Health Lawsuits Test 340B Practices And Investor Risk Assessment

CVS Health (NYSE:CVS) has been hit with two lawsuits from major hospital systems tied to the federal 340B drug discount program. The University of Kansas Hospital Authority and the University of Michigan Hospitals and Health Centers allege CVS Health improperly profited from 340B discounts. Combined claimed damages exceed $60 million, raising legal, financial, and reputational questions for the company. CVS Health comes into this legal pressure with its shares at $93.28 and a return of...